Target Joint Spontaneous annualized bleed rate (sABR) Reduction: results from a pivotal trial of once weekly BeneFIX (nonacog alfa) in Hemophilia B subjects
Awarded/Presented
Tags
Bleeding Disorders Conference
Biomedical/Coagulation Research
Researchers
Bartholomew Tortella, Marcus Carr, Pablo Rendo, Lynne Smith, Kaan Kavakli